Breaking Down SG&A Expenses: AbbVie Inc. vs Neurocrine Biosciences, Inc.

A Comparative Analysis of SG&A Expenses: AbbVie Inc. vs Neurocrine Biosciences, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: AbbVie Inc. and Neurocrine Biosciences, Inc., from 2014 to 2023.

AbbVie Inc. has consistently demonstrated a robust financial strategy, with SG&A expenses peaking at approximately $15.3 billion in 2022, marking a 98% increase from 2014. In contrast, Neurocrine Biosciences, Inc. has shown a more modest growth trajectory, with expenses rising from $18 million in 2014 to $888 million in 2023, a staggering 4,800% increase.

This stark contrast highlights the differing scales and strategies of these companies, offering valuable insights into their operational priorities and market positioning over the past decade.